EU/3/10/846 : Orphan designation for the treatment of oesophagus carcinoma



On 23 February 2011, orphan designation (EU/3/10/846) was granted by the European Commission to BTG plc, United Kingdom, for paclitaxel (aqueous gel) for the treatment of oesophagus carcinoma.

Key facts

Active substance
Intended use
Treatment of oesophagus carcinoma
Orphan designation status
EU designation number
Date of designation
BTG plc
5 Fleet Place
London EC4M 7RD
United Kingdom
Tel. + 44 (0)20 7575 0000
Fax + 44 (0)20 7575 0010

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating